Drug intelligence / Profile preview

Bi-Sai-Tong

Development stage: Preclinical
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intranasal

Overview

Bi-Sai-Tong (also known as Bi-Sai-Tong percolate or Bi-Sai-Tong solution) is a traditional Chinese medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is prepared as a liquid percolate or solution for intranasal administration. Bi-Sai-Tong is primarily developed for the treatment of moderate to severe allergic rhinitis (变应性鼻炎). Clinical studies, including a randomized parallel-group controlled trial in China, have evaluated its efficacy and safety compared to standard treatments like mometasone furoate aqueous nasal spray.

Other names: Bi-Sai-Tong percolateBi-Sai-Tong solutionBisaitong percolateBisaitong solution鼻塞通鼻塞通渗漉剂

Beyond the preview

Go deeper on Bi-Sai-Tong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bi-Sai-Tong.

Explore the full profile